Key Drivers
- Margin Strength
- Strong Liquidity
- Cash Flow Mix
AIAI Summary
LNTH looks more like a profitable, cash-generating radiodiagnostics platform than a high-risk biotech, but with Pylarify still carrying the business and the FDA CRL on LNTH-2501 exposing manufacturing/regulatory execution risk, the stock now depends on flawless delivery rather than just pipeline promise.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Strong Liquidity
- •Cash Flow Mix
LNTH shows strong profitability, liquidity, and cash generation with manageable leverage, but high intangibles, negative total cash flow, and a rich valuation temper the case.
Price Behavior
Key Price Behavior Insights:
- •Higher swing lows
- •Pullback support
- •Near resistance
LNTH remains in a strong last month uptrend with higher swing lows and improving pullback buying, but it is now pressing into near-term resistance around $110.94 and looks vulnerable to a short consolidation if momentum fades.
Recent rally from $100.25 to $109.89 suggests a stretched short-term move
Sentiment & News
Key News Insights:
- •FDA CRL
- •Manufacturing issues
- •Approval delay
Lantheus' June 2026 news was dominated by an FDA Complete Response Letter for LNTH-2501, delaying approval due to unresolved third-party manufacturing issues rather than clinical concerns.
The CRL materially pushes out LNTH-2501's launch timeline and makes manufacturing remediation the key near-term catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings